Comparison of the protective efficacy of Aujeszky's disease (pseudorabies) virus glycoproteins obtained from different sources.

The immunogenic properties of a series of glycoprotein preparations are compared using inactivated conventional vaccines as reference. Serological response and protective efficacy of vaccination of mice and pigs are evaluated for glycoprotein immunogens obtained from various sources. BHK-21 cell cultures were infected with Aujeszky's disease virus and used as antigenic source. Glycoproteins were obtained from (i) the whole culture (ii) the cell sediment and (iii) the clarified supernatant. Both in pigs and in mice, protection was greater with glycoproteins purified from infected-cell membranes than with viral mature particle glycoproteins. The specific profiles of humoral responses were basically identical regardless of the source of glycoprotein. Bartha strain, one of the gI- strains most commonly used as an attenuated vaccine, was also used as a glycoprotein source. Immunogens obtained from this strain were protective in challenge trials with the virulent E-974 strain of the Aujeszky's disease virus. Glycoproteins did not induce detectable delayed type hypersensitivity in mice but conferred greater protection than particulate antigens (which, conversely, did induce a detectable delayed type hypersensitivity reaction). Until the recent proposal of the potency criterion delta 7, no objective method was available to evaluate the degree of protection conferred by Aujeszky's disease vaccines. In this study, we thus used the protection index, a quantitative parameter designed to evaluate potency of vaccines against Aujeszky's disease virus.

Antigens involved in vaccination of swine against Aujeszky's disease (pseudorabies) virus.

The polypeptide and glycopolypeptide composition of a local virulent Aujeszky's disease virus (suid herpesvirus 1, SHV-1) strain (E-974) was determined in order to characterize the individual SHV-1 antigens inducing the serological responses in immunized and non-immunized animals. A commercially available inactivated vaccine of known efficacy and three experimental immunogen preparations (whole inactivated SHV-1 particles, lectin-purified glycoproteins from SHV-1 culture, and a combination of both) were used for immunization. Sera of two-month old immunized and non-immunized animals were analyzed by ELISA, seroneutralization and Western immunoblotting prior to and following challenge with E-974. Sera of 7- to 30-day-old piglets littered by immunized and non-immunized sows were likewise analyzed by immunoblotting. The following variables were determined: the total level of anti-SHV-1 antibodies, the level of neutralizing antibodies, the IgG responses to individual SHV-1 antigens, and the clinical parameters and degree of protection of the animals. The whole-particle experimental immunogen conferred greatest protection, but correlation between antibody levels and the degree of protection was imperfect. Serological responses seemed to be directed against certain structural polypeptides and viral envelope glycoproteins. The glycoprotein immunogen caused a selective response to bands which closely resemble the glycopolypeptides gII and gIII. A 71 kDa component of uncertain location within the viral structure appeared to be one of the main antigens involved in porcine serological response to SHV-1 and colostral protection of piglets.

Efficacy of various non-oily adjuvants in immunization against the Aujeszky's disease (pseudorabies) virus.

Standard oil and various non-oily adjuvants were compared for use in immunization against the Aujeszky's disease (pseudorabies) virus, both in mice and swine, and using either inactivated virions or purified glycoproteins as antigen. Mineral oil, sodium alginate, aluminium hydroxide, and saponin were assayed in mice as adjuvants for inactivated virions, saponin being the most efficient. The addition of Mab anti-CD3 did not improve either immune response or protection achieved in mice using viral particles with oil or sodium alginate. When purified glycoproteins were used as antigens, the use of ISCOM greatly enhanced specific T-cell responses and protection of mice. The incorporation of Mab anti-CD3 into ISCOM conferred 100% protection of mice. Surprisingly, when an ISCOM containing glycoproteins was assayed in swine in a single-dose trial, no improvement on the protection conferred by the oily adjuvant was observed.